T-Therapeutics Secures $59M in Series A Funding for Revolutionary TCR-Based Therapeutics Platform

T-Therapeutics Ltd is thrilled to announce a major funding milestone, successfully raising £59 million in a recent financing round. This next-generation T cell receptor (TCR) company, a proud spin-out from the prestigious University of Cambridge, is poised to revolutionize the landscape of immunotherapies with its innovative approach to TCR-based therapeutics. Central to our development is the proprietary OpTiMus® platform, which utilizes a fully humanized TCR mouse, enabling the generation of a virtually limitless supply of unique, antigen-specific human TCRs. The funding will be instrumental in accelerating T-Therapeutics’ mission to bring cutting-edge TCR therapies into clinical application, specifically targeting cancer and other serious diseases. By leveraging our team’s world-class expertise in mouse genome engineering, biopharmaceutical drug development, single-cell genomics, machine learning, and structural biology, we are not only advancing our therapeutic pipeline but also advancing the frontiers of immunotherapy. The investment will allow us to expand our research capabilities, enhance our development efforts, and further our commitment to delivering life-changing treatments for patients around the world. As we embark on this exciting journey, our culture of creativity and collaboration will remain at the core of our operations, driving innovation and pushing the boundaries of science to address unmet medical needs. T-Therapeutics is now positioned to make significant strides in the field of immunology, and we are grateful to our investors for their continued support in this ambitious endeavor.